For patients suffering from mid-to-late-stage Parkinson's disease, or severe heart failure that hasn't responded to conventional treatment, irreversible cell death has often meant reaching the end of available treatment options. In March 2026, Japan's Ministry of Health, Labour and Welfare formally approved two regenerative medicine products based on induced pluripotent stem (iPS) cells — the world's first time iPS cell therapy has been brought into genuine clinical application, marking a shift in the field from "pharmaceutical repair" toward a new stage of "cellular regeneration."
Amchepry, an iPS Therapy for Parkinson's Disease: Replenishing Damaged Dopamine Neurons
The root cause of Parkinson's disease is the irreversible decline of dopamine-producing neurons in the brain; conventional medications can only relieve symptoms, and their effectiveness gradually diminishes as the disease progresses. Amchepry, developed by Sumitomo Pharma in Japan, received approval through Japan's dedicated accelerated approval pathway for regenerative medicine (conditional, time-limited approval):
The therapy uses neural precursor cells cultured in vitro from Kyoto University's CiRA Foundation national iPS cell bank, which are then transplanted into the patient's brain to directly replenish damaged dopamine neurons. Officially released data shows that across 24 months of clinical follow-up, patients experienced no serious adverse events, and a number of mid-to-late-stage patients saw substantial improvement in motor symptoms. Following approval, the product will continue collecting efficacy and safety data over the next 7 years.
ReHeart, a Therapy for Severe Heart Failure: iPS Cardiomyocyte Sheets Applied to the Heart's Surface
Conventional medication and surgery often have limited effectiveness for severe heart failure, and patients frequently must wait for scarce heart transplant resources. ReHeart, a cardiomyocyte sheet therapy developed by Cuorips (an Osaka University spinoff company), received conditional approval at the same time: the research team cultures highly viable iPS-derived cardiomyocyte sheets in vitro and applies them directly to the surface of the patient's damaged heart. The sheets integrate with the existing heart tissue, improving cardiac contractile function; preclinical and early clinical research has shown clear improvement in patients' cardiac function indicators.
The Significance of Japan's Conditional Approval System for Regenerative Medicine
Japan established a dedicated approval pathway for regenerative medicine in 2014, allowing products that demonstrate safety and preliminary efficacy to reach market early (for a period of up to 7 years). Combined with one of the world's few nationally standardized iPS cell banks (CiRA), Japan leads the world in the speed of clinical translation for iPS cell technology, and international patients can be evaluated for these advanced treatment options at designated specialty medical institutions in Japan.
According to disclosures from Japanese authorities and the companies involved, both products are currently undergoing pricing assessment, with treatment expected to formally become available at select leading designated hospitals in Japan starting summer 2026.
What We Can Do for You
If you or a family member is facing mid-to-late-stage Parkinson's disease, or severe heart failure that hasn't responded to conventional treatment, MIZUHO PHARMA can help arrange a remote consultation and medical record assessment with authoritative Japanese specialists in this field, along with full support including appointment booking, medical translation, and in-person accompaniment in Japan.